2022•Value in HealthOpen access

POSB345 Updated 2018 - 2020 Review of Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration

Eva Brown Hajdukova, A Girardi, Ewelina Rzepa, K Scippa, K. Rüdell

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Orphan drug, Food and drug administration, Medicine, Perspective (graphical), Drug, Rare disease, Disease, Intensive care medicine

Back to paper search Browse research topics Original source

POSB345 Updated 2018 - 2020 Review of Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration — Research Paper | ScholarLens